# 2026年2月24日 - 专业文献速递

本期速递为您整理了最新的科研文献及AI评价，每一篇文献都包含了详细的元数据、原文摘要、中文翻译和AI的专业点评，敬请参考。

---

## 1. 慢性阻塞性肺疾病中LAMA-LABA吸入器的比较有效性与安全性研究

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41729543)
**期刊：** JAMA internal medicine
**PMID：** 41729543
**DOI：** 10.1001/jamainternmed.2025.8087

### 第一部分 原文与翻译

**英文原标题：** Comparative Effectiveness and Safety of LAMA-LABA Inhalers in Chronic Obstructive Pulmonary Disease.

> **英文摘要：**
> IMPORTANCE: Dual bronchodilator therapy with a long-acting muscarinic antagonist (LAMA) and a long-acting β2-agonist (LABA) is recommended for most patients with symptomatic chronic obstructive pulmonary disease (COPD). Fixed-dose LAMA-LABA therapies are available in metered-dose, dry powder, and soft mist inhalers. However, metered-dosed inhalers are associated with greater greenhouse gas emissions than either dry powder or soft mist inhalers, and questions persist about potential intraclass differences among LAMA-LABAs given variability in their active ingredients, dosing schedules, and delivery devices.
> 
> OBJECTIVE: To evaluate the comparative effectiveness and safety of once-daily umeclidinium-vilanterol dry powder inhalers, twice-daily glycopyrrolate-formoterol metered-dosed inhalers, and once-daily tiotropium-olodaterol soft mist inhalers.
> 
> DESIGN, SETTING, AND PARTICIPANTS: This observational active-comparator study analyzed claims of patients (≥40 years) newly treated with LAMA-LABA inhalers and continuously enrolled in a large commercial health insurance or Medicare Advantage plan during the 183-day baseline period. Patients were propensity score matched 1:1 into 3 cohorts with index dates ranging from May 1, 2016, to February 28, 2025. Data were analyzed from July to August 2025.
> 
> EXPOSURES: Patients treated with umeclidinium-vilanterol, glycopyrrolate-formoterol, or tiotropium-olodaterol fixed-dose inhalers.
> 
> MAIN OUTCOMES AND MEASURES: Time to the first moderate or severe COPD exacerbation, major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization.
> 
> RESULTS: The cohorts included 9479 matched pairs of patients receiving umeclidinium-vilanterol vs glycopyrrolate-formoterol (mean age, 68.9 [SD, 9.0] years; 10 319 women [54.4%]; 8636 men [45.6%]), 9598 receiving tiotropium-olodaterol vs glycopyrrolate-formoterol (mean age, 69.2 [SD, 8.7] years; 10 513 women [54.8%]; 8680 men [45.2%]), and 36 740 receiving umeclidinium-vilanterol vs tiotropium-olodaterol (mean age, 71.5 [SD, 8.4] years; 39 429 women [53.7%]; 34 044 men [46.3%]). Umeclidinium-vilanterol was associated with a 14% lower hazard of a first moderate or severe COPD exacerbation than glycopyrrolate-formoterol (hazard ratio [HR], 0.86; 95% CI, 0.81-0.91; number needed to treat [NNT], 17) and was associated with a 3% lower hazard than tiotropium-olodaterol (HR, 0.97; 95% CI, 0.94-0.99; NNT, 100). Tiotropium-olodaterol was associated with a 6% lower hazard of a first moderate or severe COPD exacerbation than glycopyrrolate-formoterol (HR, 0.94; 95% CI, 0.89-1.00). Similar risks of first major adverse cardiovascular event, urinary tract infection, and pneumonia hospitalization were observed among patients in all 3 cohorts.
> 
> CONCLUSIONS AND RELEVANCE: This cohort study found that umeclidinium-vilanterol was associated with improved clinical outcomes compared with glycopyrrolate-formoterol and tiotropium-olodaterol. Patients, prescribers, and health systems may consider once-daily umeclidinium-vilanterol dry powder inhalers over alternatives among new users of LAMA-LABA therapy.

> **中文摘要：**
> 重要性：长效抗胆碱能药物（LAMA）和长效β2受体激动剂（LABA）的联合支气管扩张治疗被推荐用于大多数有症状的慢性阻塞性肺疾病（COPD）患者。固定剂量的LAMA-LABA疗法有定量吸入器、干粉吸入器和软雾吸入器可选。然而，与干粉或软雾吸入器相比，定量吸入器与更多的温室气体排放相关；此外，鉴于活性成分、给药方案和递送装置的差异，关于LAMA-LABA之间潜在的类内差异问题仍然存在。
> 
> 目的：评估每日一次的乌美溴铵/维兰特罗干粉吸入器、每日两次的格隆溴铵/福莫特罗定量吸入器以及每日一次的噻托溴铵/奥达特罗软雾吸入器的比较有效性和安全性。
> 
> 设计、场所和参与者：这项观察性活性药物对照研究分析了在183天基线期内持续加入大型商业健康保险或联邦医疗保险优势计划（Medicare Advantage）、且新接受LAMA-LABA吸入器治疗的患者（≥40岁）的理赔数据。患者按倾向评分1:1匹配进入3个队列，索引日期范围为2016年5月1日至2025年2月28日。数据分析时间为2025年7月至8月。
> 
> 暴露：接受乌美溴铵/维兰特罗、格隆溴铵/福莫特罗或噻托溴铵/奥达特罗固定剂量吸入器治疗的患者。
> 
> 主要结果和衡量指标：至首次中度或重度COPD急性加重、主要不良心血管事件、尿路感染和肺炎住院的时间。
> 
> 结果：研究队列包括9479对接受乌美溴铵/维兰特罗对比格隆溴铵/福莫特罗的匹配患者（平均年龄68.9岁；女性54.4%；男性45.6%），9598对接受噻托溴铵/奥达特罗对比格隆溴铵/福莫特罗的患者（平均年龄69.2岁；女性54.8%；男性45.2%），以及36740对接受乌美溴铵/维兰特罗对比噻托溴铵/奥达特罗的患者（平均年龄71.5岁；女性53.7%；男性46.3%）。与格隆溴铵/福莫特罗相比，乌美溴铵/维兰特罗与首次中度或重度COPD急性加重风险降低14%相关（风险比[HR]为0.86；95% CI为0.81-0.91；需治疗人数[NNT]为17）；与噻托溴铵/奥达特罗相比，其风险降低3%（HR为0.97；95% CI为0.94-0.99；NNT为100）。与格隆溴铵/福莫特罗相比，噻托溴铵/奥达特罗与首次中度或重度COPD急性加重风险降低6%相关（HR为0.94；95% CI为0.89-1.00）。在所有三个队列的患者中，观察到首次主要不良心血管事件、尿路感染和肺炎住院的风险相似。
> 
> 结论和相关性：这项队列研究发现，与格隆溴铵/福莫特罗和噻托溴铵/奥达特罗相比，乌美溴铵/维兰特罗与临床结局的改善相关。对于初次使用LAMA-LABA疗法的患者，患者、处方者和医疗保健系统可以考虑优先选择每日一次的乌美溴铵/维兰特罗干粉吸入器。

### 第二部分 AI 大师评价

该研究是一项大规模的真实世界观察性研究，利用倾向评分匹配方法比较了三种不同递送装置和配方的LAMA-LABA吸入器在COPD患者中的疗效与安全性。研究发现，每日一次的乌美溴铵/维兰特罗干粉吸入器在降低中重度急性加重风险方面优于格隆溴铵/福莫特罗定量吸入器和噻托溴铵/奥达特罗软雾吸入器，且安全性指标相当。此项研究不仅为临床医生提供了关于长效双支扩剂细分选择的有力证据，还兼顾了环保因素（干粉吸入器的温室效应较低）的考量，具有重要的公共卫生和临床决策指导意义。

---

## 2. 衡量不确定性以指导限时试行：我们是否知道自己不知道什么？

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41729054)
**期刊：** Critical care medicine
**PMID：** 41729054
**DOI：** 10.1097/CCM.0000000000007082

### 第一部分 原文与翻译

**英文原标题：** Measuring Uncertainty to Inform Time-Limited Trials: Do We Know What We Don't Know?

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文聚焦于重症监护中的决策科学，探讨了如何通过量化预后的不确定性来优化限时试行（TLTs）的实施。文章深刻反思了临床医生在处理复杂预后时的认知偏差，强调了明确‘未知领域’对于制定诊疗计划和改善医患沟通的必要性。这一探讨对于提升重症医学中的伦理决策水平和医疗资源利用效率具有重要的启发意义。

---

## 3. 越多越好吗？探讨体外膜肺氧合（ECMO）中心病例量与并发症之间的关系

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41729049)
**期刊：** Critical care medicine
**PMID：** 41729049
**DOI：** 10.1097/CCM.0000000000007083

### 第一部分 原文与翻译

**英文原标题：** Is More Better? The Case of a Volume-Complication Relationship for Extracorporeal Membrane Oxygenation.

> **英文摘要：**
> No abstract available.

> **中文摘要：**
> 暂无摘要。

### 第二部分 AI 大师评价

本文深入探讨了体外膜肺氧合（ECMO）治疗领域中一个关键的管理学命题，即医疗中心的操作病例量（Volume）是否与并发症发生率存在直接关联。文章旨在分析是否存在“熟能生巧”的量效关系，以及这种关系在降低高风险生命支持技术并发症中的具体作用。虽然目前摘要不可见，但该议题对于ECMO中心的准入标准制定、医疗质量评价及区域医疗资源中心化配置具有重要的指导意义。

---

## 4. 依拉环素在小鼠模型中对耐碳青霉烯类高毒力肺炎克雷伯菌的治疗作用

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41728941)
**期刊：** Antimicrobial agents and chemotherapy
**PMID：** 41728941
**DOI：** 10.1128/aac.01237-25

### 第一部分 原文与翻译

**英文原标题：** Therapeutic effect of eravacycline against carbapenem-resistant hypervirulent  in mouse models.

> **英文摘要：**
> Carbapenem-resistant hypervirulent  (CR-hvKP) presents a major challenge for clinical treatment due to its characteristics of drug resistance and hypervirulence. This study aims to investigate the therapeutic effect of a novel tetracycline antibiotic, eravacycline, on CR-hvKP pneumonia. We isolated three CR-hvKP strains from clinical samples and examined their associated phenotypes. Subsequently, we infected mice with strains. The results indicated that the clinical isolates KP78, KP98, and KP100 carried multiple drug resistance genes and virulence genes, exhibiting high virulence levels and significantly resistant to neutrophil-mediated intracellular killing ( < 0.01). The body weight of infected mice decreased significantly ( < 0.0001). At the same time, the bacteria entered the blood from the lungs and spread to other organs. After the administration of eravacycline, the body weight of the mice began to increase 36 h later. The number of bacterial colonizing in the lungs was reduced (< 0.01), the infiltration of inflammatory cells was reduced, and the interstitial vascular dilatation and congestion were alleviated. Meanwhile, eravacycline significantly suppressed the serum levels of cytokines IL-6, IL-1β, and MCP-1 ( < 0.05). Notably, eravacycline suppressed the mRNA expression of STAT1 and p-STAT1 activation in the lung tissue of mice in the treatment group. In conclusion, clinical isolates KP78, KP98, and KP100 caused severe lung injury after invading mouse lung tissues, and eravacycline attenuated the lung injury and inflammatory response induced by CR-hvKP invasion.

> **中文摘要：**
> 耐碳青霉烯类高毒力肺炎克雷伯菌（CR-hvKP）因其耐药性和高毒力的特性，为临床治疗带来了重大挑战。本研究旨在探讨新型四环素类抗生素依拉环素（eravacycline）对CR-hvKP肺炎的治疗效果。我们从临床样本中分离出三株CR-hvKP菌株，并检查了其相关表型。随后，我们利用这些菌株感染了小鼠。结果显示，临床分离株KP78、KP98和KP100携带多种耐药基因和毒力基因，表现出高毒力水平，并对中性粒细胞介导的细胞内杀伤具有显著的抵抗力（P < 0.01）。感染小鼠的体重显著下降（P < 0.0001）。同时，细菌从肺部进入血液并扩散到其他器官。给予依拉环素后，小鼠体重在36小时后开始增加。肺部定植的细菌数量减少（P < 0.01），炎症细胞浸润减少，间质血管扩张和充血情况得到缓解。同时，依拉环素显著抑制了血清细胞因子IL-6、IL-1β和MCP-1的水平（P < 0.05）。值得注意的是，依拉环素抑制了治疗组小鼠肺组织中STAT1的mRNA表达及p-STAT1的激活。综上所述，临床分离株KP78、KP98和KP100在侵入小鼠肺组织后引起了严重的肺损伤，而依拉环素减轻了CR-hvKP侵袭诱导的肺损伤和炎症反应。

### 第二部分 AI 大师评价

本研究评价了新型四环素类药物依拉环素针对临床极难处理的耐碳青霉烯类高毒力肺炎克雷伯菌（CR-hvKP）的体内药效。通过构建小鼠肺炎模型，研究不仅证实了依拉环素能显著降低肺部细菌负荷并减少全身播散，还揭示了其通过抑制STAT1信号通路减轻炎症风暴的潜在作用机制。该发现为临床应对耐药且高毒力的“超级细菌”感染提供了重要的实验支持，具有较高的临床转化参考价值。

---

## 5. 克罗恩病相关蛋白 RNF123 通过催化 NEK7 上的非锚定 K63 连接泛素化来阻止 NLRP3 炎症小体组装

**原文链接：** [点击跳转](https://pubmed.ncbi.nlm.nih.gov/41719337)
**期刊：** Proceedings of the National Academy of Sciences of the United States of America
**PMID：** 41719337
**DOI：** 10.1073/pnas.2518759123

### 第一部分 原文与翻译

**英文原标题：** The Crohn's disease-related RNF123 prevents NLRP3 inflammasome assembly by catalyzing unanchored K63-linked ubiquitination on NEK7.

> **英文摘要：**
> The NLRP3 inflammasome is crucial for host defense against pathogen invasion and is implicated in various inflammatory disorders. The pathogenic association and the involved mechanism between the NLRP3 inflammasome and inflammatory diseases have garnered significant attention. Here, we demonstrate that Crohn's disease-associated SNP RNF123-R854H aggravates colitis in vivo through the NLRP3-dependent pathway. Deficiency of RNF123 also aggravates dextran sodium sulfate-induced colitis, LPS (lipopolysaccharide)-induced endotoxemia, and Alum-induced peritonitis and enhances host defense against bacterial infection via the NLRP3-dependent pathway in vivo and promotes the NLRP3 inflammasome activation in cells. We establish RNF123 as a regulator for the NLRP3 inflammasome, highlighting its implication in the NLRP3 inflammasome-driven inflammatory diseases. Mechanistically, RNF123 catalyzes unanchored K63-linked ubiquitination of NEK7, thereby preventing NEK7-mediated dissociation of the inactive cage-like NLRP3 aggregates and the subsequent NLRP3 inflammasome assembly. Additionally, we prove that K63-linked polyubiquitin chains can be specifically captured by NEK7 in vitro and inhibit the NEK7-licensed NLRP3 inflammasome assembly. We propose that NEK7-captured unanchored K63-polyubiquitin chains serve as a key determinant for the NLRP3 inflammasome activation, acting as a molecular brake to limit the excessive NLRP3 inflammasome activation and preserve immune homeostasis. Our work yields mechanistic insights into the NLRP3 inflammasome regulation and its pathogenic link to inflammatory disease.

> **中文摘要：**
> NLRP3 炎症小体对于宿主防御病原体入侵至关重要，并与多种炎症性疾病有关。NLRP3 炎症小体与炎症性疾病之间的致病关联及其涉及的机制已引起广泛关注。在此，我们证明克罗恩病相关的单核苷酸多态性（SNP）RNF123-R854H 通过 NLRP3 依赖性途径加重了体内结肠炎。RNF123 的缺失还会加重右旋糖酐硫酸钠诱导的结肠炎、LPS（脂多糖）诱导的内毒素血症和铝佐剂诱导的腹膜炎，并在体内通过 NLRP3 依赖性途径增强宿主对细菌感染的防御，同时在细胞中促进 NLRP3 炎症小体的激活。我们确定 RNF123 是 NLRP3 炎症小体的调节因子，强调了其在 NLRP3 炎症小体驱动的炎症性疾病中的作用。在机制上，RNF123 催化 NEK7 的非锚定 K63 连接泛素化，从而阻止 NEK7 介导的非活性笼状 NLRP3 聚集体解离以及随后的 NLRP3 炎症小体组装。此外，我们证明 K63 连接的多泛素链在体外可被 NEK7 特异性捕获，并抑制由 NEK7 许可的 NLRP3 炎症小体组装。我们提出，被 NEK7 捕获的非锚定 K63 多泛素链是 NLRP3 炎症小体激活的关键决定因素，充当限制 NLRP3 炎症小体过度激活并维持免疫稳态的分子制动器。我们的工作为 NLRP3 炎症小体的调控及其与炎症性疾病的致病联系提供了机制见解。

### 第二部分 AI 大师评价

本研究深入探讨了 RNF123 在调控 NLRP3 炎症小体激活及克罗恩病发病中的作用机制。研究发现 RNF123 通过催化 NEK7 的非锚定 K63 泛素化发挥“分子刹车”作用，阻止 NLRP3 聚集体的解离与组装，从而维持免疫稳态。该发现不仅阐明了克罗恩病相关突变 RNF123-R854H 加重炎症的生物学基础，还为以 NLRP3 为靶点的炎症性疾病治疗提供了全新的视角和分子靶点。

---

速递结束，祝您工作愉快！